Dual anti-platelet therapy in coronary artery bypass graft surgery
Phase 2
- Conditions
- coronary artery bypass graft.Presence of coronary angioplasty implant and graft
- Registration Number
- IRCT20171113037434N1
- Lead Sponsor
- Sanofi-Aventis Pharmaceutical Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 216
Inclusion Criteria
Patients Age =18 year-old
Candidate for elective coronary bypass graft surgery
Exclusion Criteria
1)Concomitant valve surgeries
2)Concomitant Aortic surgery
3)Redo-CABGs
4) Patients who don't take Aspirin at least 48 hours before surgery
5)Clopidogrel use within 5 days before CABG
6)Any condition with increased bleeding risk that precludes dual anti-platelet therapy
7)Significant bleeding in the first 4 hours after surgery
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Graft patency. Timepoint: six months after CABG surgery. Method of measurement: coronary CT angiography.
- Secondary Outcome Measures
Name Time Method The amount of chest tube output. Timepoint: four hours after surgery. Method of measurement: Measuring the chest tube drainage (it will be considered significant when its amount is more than 100 cm3 per hour in average for a 4 hours interval in ICU after surgery.).;The need for blood transfusions with either of the following:a. = 2 units of packed red blood cells b. = 2 units of fresh frozen plasma c. = 5 units of platelets. Timepoint: hospital stay duration. Method of measurement: Counting the transfused products units.;In-hospital mortality. Timepoint: hospital stay duration. Method of measurement: observation.